|
|
| Q3 (Sep '09) | 2009 | |
| Net profit margin | 20.62% | 15.42% |
| Operating margin | 31.05% | 19.92% |
| EBITD margin | - | 27.60% |
| Return on average assets | 11.20% | 8.46% |
| Return on average equity | 14.97% | 10.92% |
| Employees | 19,769 | - |
| Yasuchika Hasegawa | President, Representative Director | |
| Makoto Yamaoka | Senior Managing Director, President of Subsidiary | |
| Toyoji Yoshida | Managing Director | |
| Shigenori Ohkawa | Executive Director | |
| Alan MacKenzie | Executive Director | |
| Yasuhiko Yamanaka | Chief Director of Pharmaceutical Sales, Director |